Treatment of MOLT F4 lymphoblasts with 6-mercaptopurine (6-MP) resulted in a decrease of ATP and a depletion of S-adenosylmethionine (AdoMet). To investigate whether this might affect the methylation of DNA, we treated MOLT F4 lymphoblasts with increasing concentrations of 6-MP, followed by labeling with [methyl-
Treatment of MOLT F4 lymphoblasts with 6-mercaptopurine (6-MP) resulted in a decrease of ATP and a depletion of S-adenosylmethionine (AdoMet). To investigate whether this might affect the methylation of DNA, we treated MOLT F4 lymphoblasts with increasing concentrations of 6-MP, followed by labeling with [methyl- 14 C]methionine and [methyl-3 H]thymidine. After DNA isolation, we measured the incorporated radioactivity and determined the 14 C/ 3 H ratio as a measure for the methylation of newly formed DNA. The 14 C/ 3 H ratio was decreased by 17% with 1 mol/L 6-MP; treatment with increasing concentrations of 6-MP up to 10 mol/L showed a further decrease to 70%, in comparison with untreated cells. To demonstrate that the methylation of deoxycytidine residues in DNA was reduced, we quantified hydrolyzed DNA by HPLC. The 14 C/ 3 H ratio showed a decrease with increasing 6-MP concentrations, indicating that treatment with 6-MP resulted in hypomethylation of DNA.
6-Mercaptopurine (6-MP)
1 is a purine analog that exhibits cytotoxic activity towards malignant lymphoblasts [1, 2] . Two metabolic pathways contribute to the biotransformation and efficacy of 6-MP. 6-MP is activated intracellularly by the conversion of 6-MP into thio-IMP (tIMP) by the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase [3, 4] . Subsequently, tIMP can be converted to thiodeoxyguanosine triphosphate by means of thioguanosine monophosphate and as such be incorporated into DNA, resulting in DNA damage [5, 6] .
6-MP and its metabolites can be methylated by thiopurine methyltransferase (TPMT). The methyl donor is Sadenosyl-l-methionine (AdoMet), which is formed from adenosine triphosphate (ATP) and methionine.
We have described previously that the methylation of thiopurines leads to depletion of AdoMet [7] [8] [9] . Furthermore, methyl-tIMP is an inhibitor of de novo purine synthesis; as a consequence, ATP becomes depleted and conversion of methionine to AdoMet may be hampered [9] .
AdoMet is a universal methyl donor and is involved in the methylation of several molecules, e.g., DNA, RNA, and proteins. Depletion of AdoMet could lead to an altered methylation state and function of DNA and RNA [10] . DNA methylation can be important for the expression of genes. In general, methylation of the promoter region of a gene is associated with a block of transcription [11] .
Several studies have shown a genetic polymorphism for TPMT, with high-and low-activity alleles having been demonstrated [12, 13] . This wide interindividual variation leads to the conclusion that patients with a low TPMT activity have lesser quantities of methylated thiopurines. These patients can have an increased DNA methylation, which might result in altered gene expression. However, further investigation is needed to tell more about the relation between TPMT activity and DNA methylation.
In the present study, we determined whether exposure of leukemic cells to 6-MP affected the methylation state of newly synthesized DNA. We used the MOLT F4 cell line (a human malignant lymphoblastic T-cell line) as a model.
Materials and Methods reagents
6-MP, RNase A (type III-A, from bovine pancreas), nuclease P 1 (from Penicillium citrinum), and bacterial alkaline phosphatase (type III) were purchased from Sigma Chemical Co. Pronase was purchased from Boehringer Mannheim. RPMI 1640 medium and fetal calf serum were purchased from Life Technologies.
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with 100 mL/L nondialyzed fetal calf serum, 2 mmol/L l-glutamine, 2 mmol/L sodium pyruvate, and 50 mg/L gentamicin. The culture medium was refreshed thrice a week. The cells were maintained in a 50 mL/L CO 2 humidified atmosphere at 37°C. The absence of mycoplasma contamination and the presence of marker antigens were tested regularly.
procedures Treatment with 6-MP followed by pulse-labeling. The cells were kept in a logarithmic phase before drug exposure. The experiments started at an initial cell number of 0.3 ϫ 10 6 cells/mL. After 24-h exposure to 6-MP concentrations of 0.5, 1, 2, and 10 mol/L, the cells were transferred to a 6-well plate and radioactive pulse label was added. The final volume was 500 L. For pulse labeling we added 1.5 mmol/L l-[methyl-
14 C]methionine (DuPont NEN; 44 Ci/ mol) as methyl donor and 0.2 mol/L [methyl-
3 H]thymidine (Amersham; 52 kCi/mol) to measure newly synthesized DNA. After 4-h incubation at 37°C in the presence of the pulse labels, the cells were harvested for DNA isolation according to the method of Miller et al. [14] .
Measurement of the incorporated radioactivity. All experiments were performed in duplicate. In experiments 1-3, a small amount of the DNA solution was transferred into a counting vial and the amount of incorporated radioactivity was measured in a liquid scintillation counter. In experiment 4, to demonstrate that the methylation of deoxycytidine residues was reduced, we performed an enzymatic hydrolysis of the isolated DNA as described below. The hydrolyzed samples were then injected into the HPLC and the 5-methyldeoxycytidine and deoxythymidine fractions were collected. Radioactivity of the collected fractions was measured in a liquid scintillation counter.
DNA hydrolysis. The isolated DNA was hydrolyzed according to the method of Gehrke et al. [15] . In short, DNA was treated with nuclease P 1 and bacterial alkaline phosphatase (type III) to obtain nucleosides that could be separated and detected by HPLC. The hydrolyzed DNA was stored at Ϫ20°C until HPLC analysis.
HPLC analysis of hydrolyzed DNA. The HPLC system consisted of an isocratic pump (Thermo Separation Products) and a Supelcosil LC-18S column (25 cm ϫ 4.6 mm; 5 m particle size; Supelco). The eluent, 50 mmol/L K 2 HPO 4 (pH 4.0) with 20 mL/L methanol, was delivered to the column at a flow rate of 1 mL/min. The detector (Separations; Model 759A) was set at 285 nm ( max of 5-methyldeoxycytidine).
Results
Incubation of MOLT F4 cells with increasing concentrations of 6-MP resulted in a reduced 14 C/ 3 H ratio (Table 1 , experiments 1-3).
Treatment with 0.5 mol/L 6-MP had very little effect on the 14 C/ 3 H ratio, compared with the untreated cells (P Ͼ0.05). However, the 14 C/ 3 H ratio was decreased by 17% with 1 mol/L 6-MP, by 50% with 2 mol/L 6-MP, and by 70% with 10 mol/L 6-MP.
Radioactivity of methyldeoxycytidine and deoxythymidine was measured more specifically after DNA hydrolysis and HPLC analysis (Fig. 1) . A similar decrease of the 14 C/ 3 H ratio was found by this method (Table 1 , experiment 4). The validation of the HPLC method was tested by measuring the 14 C/ 3 H ratios of several dilutions of DNA from untreated cells and from cells treated with 6-MP. In these validation experiments we compared the results found by direct liquid scintillation counting with results found after enzymatic hydrolysis, HPLC, and liquid scintillation counting of the methyldeoxycytidine and deoxythymidine fractions. The 14 C/ 3 H ratios of both An example of a chromatogram for the HPLC analysis of hydrolyzed DNA is given in Fig. 1 . Methyldeoxycytidine and deoxythymidine were well separated.
Discussion
In a previous study in MOLT F4 human malignant lymphoblasts [9] , we showed that after 24 h of treatment with 2 mol/L 6-MP, the ATP was decreased by 55%. Incubation with 10 mol/L 6-MP resulted in a further decrease by 70% as compared with untreated cells.
We also determined [10] that, concomitantly, AdoMet was depleted and S-adenosyl-l-homocysteine (AdoHcy) and methionine were increased. The AdoMet concentration and the AdoMet/AdoHcy ratio are indications for the methylation capacity. The AdoMet/AdoHcy ratio decreased from 4.5 in untreated cells to 1.1 in cells treated with 10 mol/L 6-MP. We suggested that under these conditions a reduced methylation of DNA may occur.
Ordinarily, DNA methylation patterns are preserved to the next generations of cells. Synthesis and methylation are closely coupled processes [13] , and a reduced AdoMet concentration and a decreased AdoMet/AdoHcy ratio can interfere with these processes and lead to a reduced DNA methylation.
To investigate the effect of 6-MP on DNA methylation, we performed experiments in which we treated MOLT F4 lymphoblasts with various concentrations of 6-MP. The concentrations used were in the same range as measured in vivo during high-dose 6-MP therapy [15] .
Incubation with l-[methyl-14 C]methionine leads to formation of [methyl-
14 C]-AdoMet, which is used as methyl donor by DNA methyltransferase. As a result, [methyl-14 C] will be incorporated into DNA. The 14 C incorporation in DNA is a measure for the DNA methylation.
The synthesis of newly formed DNA is determined by the incorporation of 3 H (derived from [methyl-3 H]thymidine) into DNA. Methylation of newly formed DNA is indicated by the 14 C/ 3 H ratio. Treatment with increasing concentrations of 6-MP resulted in a decrease of the 14 C/ 3 H ratio. This, together with the fact that the formation of newly synthesized DNA was not affected under above conditions, led us to conclude that the decrease of the 14 C/ 3 H ratio is caused by a reduced incorporation of 14 C in DNA. Therefore, hypomethylation will occur during incubation with 6-MP.
As indicated previously [9] , the concentration-dependent decrease of methylation resembled the reduction of the ATP concentration with increasing concentrations of 6-MP. These effects on the DNA methylation were observed only with 6-MP concentrations Ͼ1 mol/L. 3 H]deoxythymidine into DNA, resemble the results of the first three experiments. That is, the methylation of deoxycytidine residues in DNA is reduced and hypomethylation occurs. This hypomethylation may have a great impact: New restriction sites may be created and even the expression of genes can be influenced. As pointed out, 6-MP can reverse DNA methylation and may act in two ways: First, expression of a tumor suppressor gene may be enhanced and in this way may block oncogenesis. On the other hand, 6-MP may induce hypomethylation of protogenes and may activate these genes to oncogenes; in this way, 6-MP may induce carcinogenesis. However, possible promoting effects of 6-MP on carcinogenesis have been studied recently in rats by Matsushima et al. [17] , who found no significant influence of 6-MP on carcinogenesis. Further experiments are needed to investigate the specific effect of hypomethylation by 6-MP on gene expression.
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